top of page
  • Recruiting

NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Tasquinimod

NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma


This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.


Sponsor


Collaborator

 

ClinicalTrials.gov Identifier: NCT04405167

Official Title: Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma

First Posted : May 28, 2020

Click here to see details on ClinicalTrials.gov

 

Drug: Tasquinimod

Drug: IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone

 

Tasquinimod (Code C74080)

ABR-215050

TASQ

Tasquinimod

TASQUINIMOD

 

Location

United States, Pennsylvania



Kommentare


Posts Archive
bottom of page